Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, is focused on developing new therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in San Clemente, California. Show more

ONE GLAUKOS WAY, ALISO VIEJO, CA, UNITED STATES, 92656, Aliso Viejo, CA, 92656, USA

https://www.glaukos.com

MEDICAL DEVICES

HEALTHCARE

Start AI Chat

Market Cap

9.834B

52 Wk Range

$73.16 - $184.00

Previous Close

$166.72

Open

$168.66

Volume

1,108,936

Day Range

$168.60 - $173.98

Enterprise Value

9.65B

Cash

114.5M

Avg Qtr Burn

N/A

Insider Ownership

3.61%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
travoprost-iDose® TR (IMPLANT) Details Primary open angle glaucoma , Eye disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Epioxa™ (Epi-on) Details Keratoconus	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
iDose TREX Details Eye disease , Primary open angle glaucoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Preserflo MicroShunt (Preserflo) (Glaucoma Drainage Device) Details Primary Open-Angle Glaucoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Physostigmine (GLK-321) (Cholinesterase Inhibitor) Details Demodex Blepharitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
iLution Travoprost (GLK-311) Details Eye disease , Primary open angle glaucoma	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.